Skip to main content

You are here:


Evaluate the efficacy of bimekizumab in study participants with moderate to severe HS

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

Key Eligibility Criteria

Study participants must have a diagnosis of HS for at least 6 months prior to the Baseline visit

Therapeutic Area
Hidradenitis Supperativa
Type of Study
Clinical trial
Study Status
UCB Biopharma SRL
Principal Investigator
Professor Brian Kirby